All News
Gingival Inflammation Parallels Saliva “Cytokine Score”
Researchers at NYU College of Dentistry have developed a single score to describe the level of cytokines in the saliva, and this score is linked with the severity of clinical gum inflammation, according to a study
Read Article
New Laboratory Insights for the ANA+ Consult
A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD).
Read Article
New Laboratory Insights for the ANA+ Consult
A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD).
https://t.co/Ub9pUHPRrV https://t.co/5q2yrNLD5e
Links:
Dr. John Cush RheumNow ( View Tweet)
While his talk didn’t focus on treatment, thoughtfulness regarding treatment for pain is important to our patients. Dr. Mease @RWCSmtg @RheumNow #RWCS23 https://t.co/f946SSeRWo
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. Shenoi discusses a new bio markers in sJIA lung disease. #RWCS23 @RheumNow @RWCSmtg https://t.co/Nn3KjmGNfu
Dr. Rachel Tate uptoTate ( View Tweet)
How do you treat sJIA lung disease? Lots of steroids. Lung disease may stabilize but may not resolve. Dr. Shenoi @RWCSmtg #RWCS23 @RheumNow https://t.co/d5HiRy4Ud4
Dr. Rachel Tate uptoTate ( View Tweet)
MIS-c 2023 updated diagnostic criteria broken down by information type. Dr. Shenoi #RWCS23 @RheumNow @RWCSmtg https://t.co/U24sQiEF37
Dr. Rachel Tate uptoTate ( View Tweet)
Have you heard of nipocalimab? It prevents IgG-FcRn by binding to the FcRn IgG binding site. This is one to watch in our diseases (RA, Sjogren’s, SLE, myopathies.) Dr. Postolova #RWCS23 @RheumNow @RWCSmtg https://t.co/qMGA6IdtUE
Dr. Rachel Tate uptoTate ( View Tweet)
Sex differences in neutrophils could be an interesting approach to consider with our diseases. I personally had no idea my neutrophils may be different than a males. A very interesting thought by Dr. Postolova @RWCSmtg #RWCS23 @RheumNow https://t.co/mZsFaCBk7f
Dr. Rachel Tate uptoTate ( View Tweet)
“Remote patient monitoring should be here to stay.” Here are some important codes needed for your clinical practice. #RWCS23 @RheumNow @RWCSmtg @alvinwellsmd https://t.co/dj1CpU7ChY
Dr. Rachel Tate uptoTate ( View Tweet)
Drug Safety Differences w/ New Therapies in RA
Safety outcomes for targeted synthetic or b/ts DMARDs used to treat RA were studied using data from the ARTIS registry.
https://t.co/U96LiasMhW https://t.co/f2oCHs04Q3
Links:
Dr. John Cush RheumNow ( View Tweet)
Comparison of MIS-C dz in kids and adults>21 (MISC - A). By Dr Susan Shenoi @RWCSmtg #rwcs23 https://t.co/jvsMLARkCA
Dr. John Cush RheumNow ( View Tweet)
Case reports of anifrolumab use in 2 pts w/ chronic, scarring discoid lupus unresponsive to steriods, HCQ, immunosuppressants & CTX. Case 1 SLEDAI from 13 to 2 in 24 weeks & CLASI-A from 26 to 3 in 20wks. Cs 2 CLASI-A decr 24 to 5 after 1 infusion https://t.co/JE3PVyskm4
Links:
Dr. John Cush RheumNow ( View Tweet)
Older Lupus Patients Need Follow-Up After Hospital Discharge
Medicare beneficiaries 65 and older with lupus faced dramatically higher mortality when they received no follow-up care during the month after a hospital stay, researchers found.
https://t.co/4mFctXGQH9 https://t.co/2Q1z03myud
Links:
Dr. John Cush RheumNow ( View Tweet)
It's time to play, know your numbers! You know that famous game we play almost every other week, every other year.
https://t.co/JgCJzSuzHZ https://t.co/oiyB8vCOuD
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 232 pediatric #SLE pts. Over 12 mos 47% achieved LLDAS & Damage seen in 40% after 6.2 yrs F/U. Getting to LLDAS w/in 12 mos is assoc w less damage. LLDAS w/in 12 mos more likely in Absence of renal involvement. https://t.co/pGethJCw4e https://t.co/eYpVueIKbf
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheums: Treating #RA, Do you Consider/Use RA Rx guidelines?
Dr. John Cush RheumNow ( View Tweet)
On Dec. 19, 2022, the U.S. Food & Drug Administration (FDA) approved subcutaneous abaloparatide (Tymlos) for the treatment of men with osteoporosis at high risk of fracture https://t.co/igwxVCdKuo https://t.co/COSmDrsv4p
Links:
Dr. John Cush RheumNow ( View Tweet)
Alternatives to Vagal nerve stimulation Dr Eric Ruderman #RWCS23 @RWCSmtg https://t.co/zpJsh10LLQ
Dr. John Cush RheumNow ( View Tweet)
2nd study results with Implantable Vagal nerve stim in active #RA pts. Dr Eric Ruderman #RWCS23 https://t.co/S6aFSVjePD
Dr. John Cush RheumNow ( View Tweet)